98 related articles for article (PubMed ID: 9290954)
41. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Hanby AM; Kelsell DP; Potts HW; Gillett CE; Bishop DT; Spurr NK; Barnes DM
Int J Cancer; 2000 Oct; 88(2):204-8. PubMed ID: 11004669
[TBL] [Abstract][Full Text] [Related]
42. Identification of a microsatellite instability phenotype in meningiomas.
Pykett MJ; Murphy M; Harnish PR; George DL
Cancer Res; 1994 Dec; 54(24):6340-3. PubMed ID: 7987826
[TBL] [Abstract][Full Text] [Related]
43. BRCA2 protein expression in sporadic breast carcinoma with or without allelic loss of BRCA2.
Bernard-Gallon D; Peffault De Latour M; Rio P; Favy D; Hizel C; Vissac C; Bignon YJ
Int J Cancer; 2000 May; 86(4):453-6. PubMed ID: 10797254
[TBL] [Abstract][Full Text] [Related]
44. Loss of heterozygosity for chromosome 22 DNA sequences in human meningioma.
Cogen PH; Daneshvar L; Bowcock AM; Metzger AK; Cavalli-Sforza LL
Cancer Genet Cytogenet; 1991 Jun; 53(2):271-7. PubMed ID: 1676608
[TBL] [Abstract][Full Text] [Related]
45. Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay.
Ban S; Shinohara T; Hirai Y; Moritaku Y; Cologne JB; MacPhee DG
Mutat Res; 2001 Mar; 474(1-2):15-23. PubMed ID: 11239959
[TBL] [Abstract][Full Text] [Related]
46. Chromosome 22 heterozygosity is retained in most hyperdiploid and pseudodiploid meningiomas.
Bello MJ; de Campos JM; Vaquero J; Kusak ME; Sarasa JL; Rey JA; Pestaña A
Cancer Genet Cytogenet; 1993 Apr; 66(2):117-9. PubMed ID: 8500098
[TBL] [Abstract][Full Text] [Related]
47. Molecular prognostic markers in breast cancer.
Dahiya R; Deng G
Breast Cancer Res Treat; 1998; 52(1-3):185-200. PubMed ID: 10066082
[TBL] [Abstract][Full Text] [Related]
48. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer.
Prechtel D; Werenskiold AK; Prechtel K; Keller G; Höfler H
Diagn Mol Pathol; 1998 Feb; 7(1):57-62. PubMed ID: 9646036
[TBL] [Abstract][Full Text] [Related]
49. Clonal analysis of meningiomas.
Wu JK; MacGillavry M; Kessaris C; Verheul B; Adelman LS; Darras BT
Neurosurgery; 1996 Jun; 38(6):1196-200; discussion 1200-1. PubMed ID: 8727151
[TBL] [Abstract][Full Text] [Related]
50. [Sporadic familial meningiomas].
Medrano-Martínez V; Moltó-Jordà JM; Sánchez-Pérez RM; Castaño-Pérez MD; Arenas J; Beltrán-Blasco I
Rev Neurol; 2000 Sep 1-15; 31(5):433-5. PubMed ID: 11027095
[TBL] [Abstract][Full Text] [Related]
51. Expression of androgen and progesterone receptors in primary human meningiomas.
Maxwell M; Galanopoulos T; Neville-Golden J; Antoniades HN
J Neurosurg; 1993 Mar; 78(3):456-62. PubMed ID: 8433149
[TBL] [Abstract][Full Text] [Related]
52. Molecular pathology of ovarian carcinomas.
Matias-Guiu X; Prat J
Virchows Arch; 1998 Aug; 433(2):103-11. PubMed ID: 9737787
[TBL] [Abstract][Full Text] [Related]
53. Loss of heterozygosity and the origin of meningioma.
Meese E; Blin N; Zang KD
Hum Genet; 1987 Dec; 77(4):349-51. PubMed ID: 2891603
[TBL] [Abstract][Full Text] [Related]
54. Enhanced expression of the c-myc protooncogene in human intracranial meningiomas.
Kim JH; Lee SH; Cho KJ; Jang JJ; Hong SI; Lee JH
J Korean Med Sci; 1993 Feb; 8(1):68-72. PubMed ID: 8343222
[TBL] [Abstract][Full Text] [Related]
55. Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene.
Peyrard M; Fransson I; Xie YG; Han FY; Ruttledge MH; Swahn S; Collins JE; Dunham I; Collins VP; Dumanski JP
Hum Mol Genet; 1994 Aug; 3(8):1393-9. PubMed ID: 7987321
[TBL] [Abstract][Full Text] [Related]
56. Hypermethylation of
Lombardi IAS; Faria MHG; Rabenhorst SHB; Zanini MA; DE Moura Campos Pardini MI; Grotto RMT; Ferrasi AC
Anticancer Res; 2018 May; 38(5):2819-2822. PubMed ID: 29715104
[TBL] [Abstract][Full Text] [Related]
57. [Meningiomas and their cytogenetic implication].
Portero JA; García Quesada L; Rey JA; Ayuso C
Rev Clin Esp; 1980 Jul; 157(5):305-8. PubMed ID: 7403603
[No Abstract] [Full Text] [Related]
58. BRCA 1/2 gene mutation testing-based cancer prevention and the moral concerns of different types of patients.
Goelen G; Rigo A; Bonduelle M; De Grève J
Ann N Y Acad Sci; 1999; 889():240-3. PubMed ID: 10668499
[No Abstract] [Full Text] [Related]
59. Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators.
Edwards SM; Dunsmuir WD; Gillett CE; Lakhani SR; Corbishley C; Young M; Kirby RS; Dearnaley DP; Dowe A; Ardern-Jones A; Kelly J; Spurr N; Barnes DM; Eeles RA
Int J Cancer; 1998 Sep; 78(1):1-7. PubMed ID: 9724085
[TBL] [Abstract][Full Text] [Related]
60. Altered restriction pattern of the putative DNA binding domain of estrogen receptor or related genes in primary human meningiomas.
Vacca A; Fazio VM; Gandini O; Oppido P; Delfini R; Frati L; Gulino A
Int J Cancer; 1989 Apr; 43(4):567-9. PubMed ID: 2703268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
